National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia.
Warren Alpert Medical School, Brown University, Providence, Rhode Island.
JAMA Psychiatry. 2020 May 1;77(5):493-502. doi: 10.1001/jamapsychiatry.2019.4170.
Extramedical opioid use has escalated in recent years. A better understanding of cause-specific mortality in this population is needed to inform comprehensive responses.
To estimate all-cause and cause-specific crude mortality rates (CMRs) and standardized mortality ratios (SMRs) among people using extramedical opioids, including age- and sex-specific estimates when possible.
For this systematic review and meta-analysis, MEDLINE, PsycINFO, and Embase were searched for studies published from January 1, 2009, to October 3, 2019, and an earlier systematic review on this topic published in 2011.
Cohort studies of people using extramedical opioids and reporting mortality outcomes were screened for inclusion independently by 2 team members.
Data were extracted by a team member and checked by another team member. Study quality was assessed using a custom set of items that examined risk of bias and quality of reporting. Data were pooled using random-effects meta-analysis models. Heterogeneity was assessed using stratified meta-analyses and meta-regression.
Outcome measures were all-cause and cause-specific CMRs and SMRs among people using extramedical opioids compared with the general population of the same age and sex.
Of 8683 identified studies, 124 were included in this analysis (100 primary studies and 24 studies providing additional data for primary studies). The pooled all-cause CMR, based on 99 cohorts of 1 262 592 people, was 1.6 per 100 person-years (95% CI, 1.4-1.8 per 100 person-years), with substantial heterogeneity (I2 = 99.7%). Heterogeneity was associated with the proportion of the study sample that injected opioids or was living with HIV infection or hepatitis C. The pooled all-cause SMR, based on 43 cohorts, was 10.0 (95% CI, 7.6-13.2). Excess mortality was observed across a range of causes, including overdose, injuries, and infectious and noncommunicable diseases.
The findings suggest that people using extramedical opioids experience significant excess mortality, much of which is preventable. The range of causes for which excess mortality was observed highlights the multiplicity of risk exposures experienced by this population and the need for comprehensive responses to address these. Better data on cause-specific mortality in this population in several world regions appear to be needed.
近年来,非医疗用途的阿片类药物滥用急剧上升。为了制定全面的应对措施,有必要更好地了解此类人群的特定死因死亡率。
评估包括年龄和性别特异性估计值在内的非医疗用阿片类药物使用者的全因和特定原因粗死亡率(CMR)和标准化死亡率比(SMR)。
本系统评价和荟萃分析检索了 2009 年 1 月 1 日至 2019 年 10 月 3 日期间发表的 MEDLINE、PsycINFO 和 Embase 中的研究,并纳入了 2011 年发表的一篇关于该主题的早期系统评价。
由两名团队成员独立筛选了关于非医疗用阿片类药物使用者和报告死亡率结果的队列研究。
由一名团队成员提取数据,另一名团队成员进行核对。使用一套专门的评估工具评估研究质量,这些工具检查了偏倚风险和报告质量。使用随机效应荟萃分析模型对数据进行汇总。使用分层荟萃分析和荟萃回归评估异质性。
结局指标是与同龄和同性别一般人群相比,非医疗用阿片类药物使用者的全因和特定原因 CMR 和 SMR。
在 8683 项已识别的研究中,有 124 项研究纳入了本分析(100 项主要研究和 24 项为主要研究提供额外数据的研究)。基于 99 项包含 1262592 人的队列研究,全因 CMR 的汇总值为 1.6/100 人年(95%CI,1.4-1.8/100 人年),异质性很大(I2=99.7%)。异质性与研究样本中注射阿片类药物或感染艾滋病毒或丙型肝炎的比例有关。基于 43 项队列研究的全因 SMR 汇总值为 10.0(95%CI,7.6-13.2)。观察到各种原因导致的超额死亡率,包括过量用药、伤害和传染性及非传染性疾病。
研究结果表明,非医疗用阿片类药物使用者的死亡率显著升高,其中大部分是可以预防的。观察到的超额死亡率涉及多种原因,突出了该人群所经历的多种风险暴露,需要采取综合措施来应对这些风险。似乎需要在世界多个地区获得该人群特定死因死亡率的更好数据。